New Diagnostic Addresses Critical Gap in IVF Care with Personalized Endometrial Fertility Test

Strategic Insights -

Simbryo Technologies, a biotech company improving in-vitro fertilization (IVF) outcomes, has announced the availability of Simbryo FX, a personalized functional assay of endometrial fertility that predicts the likelihood of implantation before embryo transfer. This innovation addresses a critical gap in IVF care, where current endometrial tests are ineffective in predicting endometrial fertility.

One in six couples worldwide struggles with infertility, and despite advances in embryo testing, IVF success rates have plateaued at 65 percent. Many unsuccessful embryo transfers stem from issues with the endometrium, the uterine lining where embryos implant and develop. Simbryo FX assesses endometrial fertility by creating organoids, three-dimensional models of the endometrium, and implanting blastoids to quantify endometrial fertility through hCG levels and imaging.

Key Takeaways:

  • Simbryo FX accurately identifies patients at risk for failed transfers with over 90% specificity, enabling personalized treatment decisions.
  • The test predicts the outcomes of patients' next embryo transfer in the clinic: nearly all of those in the low fertility group experienced another failed transfer.
  • Simbryo FX CORRELATED WITH THE LIKELIHOOD OF EMBRYO TRANSFER SUCCESS, and among the remaining patients, assay scores correlated with the likelihood of embryo transfer success.
  • The assay identifies patients with low endometrial fertility with over 90% specificity, and predicts the outcomes of patients' next embryo transfer in the clinic.
  • Current endometrial tests assess endometrial inflammation, harmful bacteria, or altered hormone timing, but they are not effective clinical predictors of endometrial fertility.
  • Simbryo FX enables true personalized medicine in IVF by using a patient's biopsy tissue to create organoids, making results and insights patient-specific.

Statistics:

  • 65%: current IVF success rate
  • 1 in 6: couples worldwide struggling with infertility
  • 90%: specificity of Simbryo FX in identifying patients at risk for failed transfers
  • 3 or more: number of prior failed transfers identified by Simbryo FX
  • 100: number of patients analyzed in the clinical study

Sources:

  • GlobeNewswire: "Simbryo Technologies Introduces Simbryo FX, a First-in-Class Personalized Functional Assay for Endometrial Fertility"
  • Simbryo Technologies: "Simbryo FX: Personalized Endometrial Fertility Test for IVF"
  • American Society of Reproductive Medicine (ASRM): "Scientific Congress in San Antonio"
  • Texas Fertility Center: "Endometrial Fertility Evaluation During IVF Cycles"
  • Aspire HFI: "Identifying Why Implantation is Not Successful and Adjusting Treatment Plans Beforehand"